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The 3-substituted indoles are structural units of many natural and biologically interesting compounds, which possess various pharmacological activities. 1−4 The indole derivatives serve as a scaffold in a number of antibacterial, 5 antiviral, 6 and protein kinase inhibitors. 7 Indole-based derivatives have been investigated for anticancer activities. Indole-3-carbinols have been previously reported to exhibit anticancer activities against a number of human cancers through acting on different cellular signaling pathways. 8 1-Aroylindoles and 3-aroylindoles have shown potent cytotoxicity against different human cancer cell lines. 9 Several indole derivatives have shown tyrosine kinase inhibition in low micromolar range. 7 ,10 3-Substituted 2,2′-dithiobis(1H-indoles) have been reported to show inhibition against protein tyrosine kinases (PTKs), such as EGFR and non receptor v-Src tyrosine kinases.
11 SU5416 (Fig. 1 ) is an indole-based FIK-1/KDR inhibitor, and is currently in clinical trials against ovarian cancer.
12−14
The Src family of tyrosine kinases (SFKs) is comprised of nine tyrosine kinases viz., Src, Lck, Fyn, Yes, Hck, Blk, Fgr, Lyn, and Yrk. SFKs have critical roles in multiple signaling pathways that control a diverse spectrum of biological activities, such as growth factor signaling, cell growth, division, differentiation, survival, adhesion, migration, and invasion. 16 c-Src tyrosine kinase is the prototype of SFKs. c-Src upregulation has been observed in a number of epithelial tumors, such as ovary, colon, lung, breast, prostate, and pancreas when compared with the normal tissues. c-Src serves as a key modulator of cancer cell invasion and metastasis through reducing cell adhesion and facilitating motility. 17−19 Thus, considerable interest has been evolved around the design of Src kinase inhibitors for the treatment of cancer and anti-invasion therapy. 20 A number of small molecule inhibitors 21−22 have shown potential biological activity as both antiproliferative and anti-invasive agents in preclinical studies in different solid tumor types. In continuation of our efforts towards the development of organic transformations catalyzed by metal triflates 27 and synthesis of small molecules as anticancer agents and/or c-Src kinase inhibitors, 15, 28 herein we report an expeditious one-pot synthesis of 3-substituted indoles by three component condensation catalyzed by Yb(OTf) 3 −SiO 2 (Scheme 1) and evaluation of their anticancer and c-Src kinase inhibitory activity. 4 ], using Yb(OTf) 3 −SiO 2 as a catalyst. Among these solvents acetonitrile was found to be most efficient reaction media to give 4a in good yield (88%) while the reaction yield in other solvents was very poor.
Furthermore, catalyst conditions were optimized by using different variations of catalyst, catalyst loading, and time period of reaction ( Table 1 ). The yield of 4a was poor and required longer time when reaction was performed with either Yb(OTf) 3 or silica gel alone. Among the screened catalysts Yb(OTf) 3 −SiO 2 (5−10 mol %), Ce(OTf) 3 −SiO 2 (5 mol %), and Cu(OTf) 2 −SiO 2 (5 mol %) were found to give good yield of 4a. The Yb(OTf) 3 −SiO 2 (5 mol %) gave the highest yield (88%) of 4a and, therefore, further studies were carried out using this as a catalyst of choice. In case of other acidic catalysts supported on silica gel such as pTSA−SiO 2 (71%), FeCl 3 −SiO 2 (59%) the yield of 4a was moderate but accompanied with generation of bis(indolyl)methane (5−30%) as a side product. The standardized reaction conditions were used further for the synthesis of different 3-substituted indole derivatives. 29 Indole or N-methylindole, Nmethylaniline, and a substituted or unsubstituted benzaldehyde were reacted to obtain 3-substituted indole derivatives (4a−r). The products and their yields are summarized in Table 2 . All the compounds were characterized by 1 H NMR, 13 C NMR, and mass spectroscopy. The reaction is assumed to proceed through formation of imine through reaction of the benzaldehyde and N-methylaniline followed by nucleophilic attack of indole to give 3-substituted indoles as shown in Scheme 2. The structure of product is consistent with the synthesis of 3-substituted indoles via multicomponent condensation reaction of indoles, aldehyde, and amines. An array of 18 diversely substituted indoles was evaluated against Src kinase. The results of Src kinase inhibitory activity of compounds (4a− − − −r) are shown in Table 2 . Among all the screened compounds, 4d, 4j, 4k, 4l, and 4r showed modest inhibition of Src kinase with IC 50 values of 50.6−98.3 µM. The data suggest that the presence of either electron donating or electron withdrawing groups on the phenyl ring (R′′ position) was mostly less tolerated as shown in compounds 4a− − − −c, 4e− − − −i, and 4n− − − −p with IC 50 value of ≥100 µM. The unsubstituted indole derivative 4d showed an IC 50 value of 50.6 µM while introduction of electron withdrawing group -NO 2 at 3-position of phenyl ring (4l) exhibited comparable inhibitory activity (IC 50 = 58.3 µM).
DS visualizer docking studies 31 were used to study the interactions of 4d with the ATP binding site of the Src kinase. Compound 4d was superimposed on a reference anilinoquanzoline AZD05030, a dual specific c-Src/Abl kinase inhibitor 32 in complex with the Src kinase (PDB 2H8H). As can be seen from Figure 2 , 4d interacts with the ATP binding pocket in slightly different orientation when compared with reference quinazoline ligand. The chloro group in reference ligand oriented towards and interacts with Ala403, whereas in 4d phenyl rings lie in hydrophobic binding pocket. N 1 −H of indole ring in compound 4d shows specific hydrogen bonding interaction with Ile336. The hydrogen bonding interaction was not observed when N1 was methylated in 4i. This interaction may have contributed to higher inhibitory activity of unmethylated compounds 4d (IC 50 = 50.6 µM) versus N1-methylated analog 4i (IC 50 > 150 µM). On the other hand, N 1 -methylated compounds 4j and 4k exhibited improved inhibition activity versus 4a and 4b, respectively ( Table 2 ), suggesting that hydrophobic interactions of methyl with Ile336 may also contribute to modest inhibitory activity. The binding energy for 4d was observed as -7.42 kcal/mol and estimated inhibition constant at 3.67 µM while the reference ligand binding energy and estimated inhibition constant were -7.36 kcal/mol and 4.01 µM, respectively. The RMSD from reference ligand is 1.230 Ǻ.
The effect of the compounds on the cell proliferation of human ovarian adenocarcinoma (SK-OV-3) and colon adenocarcinoma (HT-29) cancer cells that also overexpress c-Src, 33, 34 was also evaluated at the concentration of 50 µM (Fig. 3) . In general, most of the compounds were more active against SK-OV-3 cells than HT-29 cells. Indole-based SU5416 is also currently in clinical trials against ovarian cancer. Consistently compounds 4o− − − −r inhibited the cell proliferation of both cancer cells significantly while 4a only inhibited SK-OV-3. The 4-methylphenyl (4o and 4p) and 4-methoxyphenyl (4q) indole derivatives inhibited the cell proliferation of SK-OV-3 and HT-29 cells by 70−77% whereas 4-cholorderivatives 4a and 4r inhibited the growth of ovarian cancer cells (SK-OV-3) by approximately 72% and 77%, respectively (Fig. 3) . Structure−activity relationship studies suggest that the presence of bromo-or methoxy-substituent at position 5 of indole ring (R) in addition to methyl, methoxy, or chloro substitutent at as R′′ is critical for maximum anticancer activity as seen in compounds 4o− − − −r. In general, poor correlation was observed between Src kinase inhibitory potency of the compounds and the inhibition of cell proliferation in cancer cells, suggesting that differential cellular uptake and contribution of other mechanisms in anticancer activities of these compounds. Compounds 4d and 4r that showed modest Src kinase inhibition, also inhibited the growth of SK-OV-3 by 55% and 77%, respectively.
In conclusion, we have developed an ecofriendly and economical method for the synthesis of 3-substituted indoles by one pot three-component coupling reaction of a benzaldehyde, N-methylaniline, and indole or N-methylindole using Yb(OTf) 3 −SiO 2 as catalyst. To the best of our knowledge, this is the first report of the synthesis and evaluation of 3-substituted indole derivatives as Src kinase inhibitors and anticancer agents. The compounds 4d, 4j, 4k, 4l, and 4r showed modest inhibition of Src kinase while compounds 4o− − − −r inhibited the cell proliferation of ovarian and colon cancer cells significantly. Structure−activity relationship studies revealed the importance of the presence of a substituent at position 5 of indole ring (R) for anticancer activity. This study provides insights for further optimizing of substituted indoles for the discovery of the Src kinase inhibitors and/or anticancer agents. 
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